ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
FES eQTL suppresses the progression of primary aldosteronism by regulating CD3 on TD CD8br immune cells: Mendelian randomization and mediation analysis.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of primary aldosteronism (PA) remains incompletely understood. Current pharmacological therapies have significant limitations, thus highlighting the importance of recognizing new therapeutic targets for the diagnosis and treatment of PA. This study employed two-sample Mendelian randomization (MR) analysis, colocalization, summary data-based Mendelian randomization (SMR) analysis, and mediation analysis to recognize new therapeutic targets for the diagnosis and treatment of PA. Our analysis revealed a significant positive connection between increased FES eQTL expression and reduced PA risk. Concurrently, to elucidate the underlying metabolic mechanisms through which the FES eQTL influences PA, we identified immune cells as significant mediators of this pathway. Specifically, The FES eQTL was found to elevate the risk level of CD3 expression on TD CD8br immune cells (OR = 1.116885, 95% CI = 1.037747-1.202059, p = 3.20E-03), whereas elevated CD3 expression on TD CD8br immune cells reduced the risk of PA (OR = 0.6382, 95% CI = 0.428972-0.949479, p = 2.67E-02). On the basis of the aforementioned relationships, we ultimately determined that FES suppresses PA through a potential metabolic mechanism that involves immune cell modulation. We identified and verified the FES eQTL as a new cis-eQTL-mediated susceptibility gene that can reduce the risk of PA among druggable genes. Concurrently, we observed that the FES eQTL suppresses PA through a potential metabolic mechanism that involves the regulation of CD3 on TD CD8br immune cells, thereby providing a new therapeutic target for PA diagnosis and treatment.
Indexed as
Identifiers
42115443What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.